Equities Analysts Issue Forecasts for PLRX FY2029 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Equities researchers at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a report released on Monday, February 10th. HC Wainwright analyst E. Arce anticipates that the company will earn $1.75 per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.65) per share.

A number of other research firms have also commented on PLRX. Canaccord Genuity Group restated a “hold” rating and issued a $4.00 price objective (down from $43.00) on shares of Pliant Therapeutics in a research note on Monday. Needham & Company LLC lowered their price target on Pliant Therapeutics from $38.00 to $10.00 and set a “buy” rating on the stock in a report on Monday. Royal Bank of Canada downgraded Pliant Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $45.00 to $4.00 in a research note on Monday. Citigroup cut Pliant Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $40.00 to $4.00 in a research report on Monday. Finally, Oppenheimer reissued a “market perform” rating on shares of Pliant Therapeutics in a report on Monday. Seven investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $17.75.

Pliant Therapeutics Stock Up 21.0 %

PLRX stock opened at $3.29 on Wednesday. The company has a market cap of $200.20 million, a price-to-earnings ratio of -0.99 and a beta of 1.03. The company has a fifty day moving average price of $11.94 and a 200 day moving average price of $12.72. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26. Pliant Therapeutics has a 12 month low of $2.43 and a 12 month high of $18.00.

Insider Transactions at Pliant Therapeutics

In other news, General Counsel Mike Ouimette sold 10,230 shares of the company’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $10.99, for a total transaction of $112,427.70. Following the transaction, the general counsel now directly owns 70,544 shares of the company’s stock, valued at $775,278.56. This represents a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Hans Hull sold 15,936 shares of the firm’s stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $11.20, for a total transaction of $178,483.20. Following the completion of the sale, the insider now owns 211,558 shares of the company’s stock, valued at $2,369,449.60. This trade represents a 7.01 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 91,855 shares of company stock valued at $1,026,628. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pliant Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of PLRX. Harbor Capital Advisors Inc. raised its holdings in Pliant Therapeutics by 233.8% during the third quarter. Harbor Capital Advisors Inc. now owns 91,979 shares of the company’s stock worth $1,031,000 after purchasing an additional 64,422 shares during the last quarter. Atria Investments Inc purchased a new position in shares of Pliant Therapeutics in the third quarter valued at $112,000. State Street Corp raised its stake in shares of Pliant Therapeutics by 1.9% during the 3rd quarter. State Street Corp now owns 1,402,730 shares of the company’s stock worth $15,725,000 after buying an additional 26,610 shares during the last quarter. Polar Asset Management Partners Inc. boosted its position in shares of Pliant Therapeutics by 265.2% in the 3rd quarter. Polar Asset Management Partners Inc. now owns 170,200 shares of the company’s stock worth $1,908,000 after buying an additional 123,600 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in Pliant Therapeutics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,318,308 shares of the company’s stock valued at $14,781,000 after acquiring an additional 31,221 shares during the last quarter. Institutional investors and hedge funds own 97.30% of the company’s stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.